Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
rivastigmine hydrogen tartrate, Quantity: 2.4 mg
Arrotex Pharmaceuticals Pty Ltd
rivastigmine hydrogen tartrate
Capsule
Excipient Ingredients: titanium dioxide; stearic acid; iron oxide yellow; maize starch; Gelatin; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide
Oral
100, 56, 500
(S4) Prescription Only Medicine
Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type
Visual Identification: Hard gelatine calsule with yellow, opaque body and yellow opaque cap. Imprinted "APO R1.5" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2010-07-27